PMID- 34409847 OWN - NLM STAT- MEDLINE DCOM- 20220404 LR - 20220531 IS - 1557-7716 (Electronic) IS - 1523-0864 (Linking) VI - 36 IP - 1-3 DP - 2022 Jan TI - Insufficient S-Sulfhydration of Methylenetetrahydrofolate Reductase Contributes to the Progress of Hyperhomocysteinemia. PG - 1-14 LID - 10.1089/ars.2021.0029 [doi] AB - Aims: Hyperhomocysteinemia (HHcy) has been considered as a risk factor for cardiovascular disease, Alzheimer's disease, nonalcoholic fatty liver, and many other pathological conditions. Vitamin B6, Vitamin B12, and folate have been used to treat HHcy in clinics. However, at present, clinical therapies of HHcy display unsatisfactory effects. Here, we would like to explore a new mechanism involved in homocysteine (Hcy) metabolic disorders and a novel target for HHcy treatment. The key enzymes involved in Hcy metabolism deserve more insightful investigation. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme regulating the intracellular Hcy metabolism. Until now, the effect of post-translational modification on the bioactivity of MTHFR still remains unclear. This study aimed at exploring the relationship between MTHFR S-sulfhydration and its bioactivity, and at identifying the contribution of an elevated Hcy level on MTHFR bioactivity. Results: By both in vivo and in vitro studies, we observed the following results: (i) The bioactivity of MTHFR was positively associated with its S-sulfhydration level; (ii) MTHFR was modified at Cys32, Cys130, Cys131, Cys193, and Cys306 by S-sulfhydration under physiological conditions; (iii) Hydrogen sulfide (H(2)S) deficiency caused the decrease of MTHFR S-sulfhydration level and bioactivity in HHcy, which resulted in further aggravation of HHcy; and (iv) H(2)S donors reversed the decreased bioactivity of MTHFR in HHcy, thus reducing the excessive Hcy level. Innovation and Conclusion: Our study suggested that H(2)S could improve MTHFR bioactivity by S-sulfhydration, which might provide a candidate therapeutic strategy for HHcy. Antioxid. Redox Signal. 36, 1-14. FAU - Ji, Dengyu AU - Ji D AD - Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory for Metabolic Disorder-Related Cardiovascular Diseases, Beijing, China. FAU - Luo, Chenghua AU - Luo C AD - Department of Pathology and Key Laboratory for Xinjiang Endemic and Ethnic Diseases, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, China. FAU - Liu, Jing AU - Liu J AD - Department of Clinical Laboratory, Xuanwu Hospital, Capital Medical University, Beijing, China. FAU - Cao, Yan AU - Cao Y AD - Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory for Metabolic Disorder-Related Cardiovascular Diseases, Beijing, China. FAU - Wu, Jiangxu AU - Wu J AD - Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory for Metabolic Disorder-Related Cardiovascular Diseases, Beijing, China. FAU - Yan, Wenjing AU - Yan W AD - Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory for Metabolic Disorder-Related Cardiovascular Diseases, Beijing, China. FAU - Xue, Ke AU - Xue K AD - Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory for Metabolic Disorder-Related Cardiovascular Diseases, Beijing, China. FAU - Chai, Jiayin AU - Chai J AD - Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory for Metabolic Disorder-Related Cardiovascular Diseases, Beijing, China. FAU - Zhu, Xinyu AU - Zhu X AD - Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory for Metabolic Disorder-Related Cardiovascular Diseases, Beijing, China. FAU - Wu, Ye AU - Wu Y AD - Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory for Metabolic Disorder-Related Cardiovascular Diseases, Beijing, China. FAU - Liu, Huirong AU - Liu H AD - Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory for Metabolic Disorder-Related Cardiovascular Diseases, Beijing, China. FAU - Wang, Wen AU - Wang W AUID- ORCID: 0000-0003-4120-0773 AD - Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, China. AD - Beijing Key Laboratory for Metabolic Disorder-Related Cardiovascular Diseases, Beijing, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20211217 PL - United States TA - Antioxid Redox Signal JT - Antioxidants & redox signaling JID - 100888899 RN - 0LVT1QZ0BA (Homocysteine) RN - 935E97BOY8 (Folic Acid) RN - EC 1.5.1.20 (MTHFR protein, human) RN - EC 1.5.1.20 (Methylenetetrahydrofolate Reductase (NADPH2)) RN - P6YC3EG204 (Vitamin B 12) SB - IM MH - Folic Acid/therapeutic use MH - Homocysteine MH - Humans MH - *Hyperhomocysteinemia/complications MH - *Methylenetetrahydrofolate Reductase (NADPH2)/genetics/metabolism MH - Oxidation-Reduction MH - Vitamin B 12/physiology/therapeutic use OTO - NOTNLM OT - S-sulfhydration OT - folate OT - hydrogen sulfide OT - hyperhomocysteinemia OT - methylenetetrahydrofolate reductase EDAT- 2021/08/20 06:00 MHDA- 2022/04/05 06:00 CRDT- 2021/08/19 08:37 PHST- 2021/08/20 06:00 [pubmed] PHST- 2022/04/05 06:00 [medline] PHST- 2021/08/19 08:37 [entrez] AID - 10.1089/ars.2021.0029 [doi] PST - ppublish SO - Antioxid Redox Signal. 2022 Jan;36(1-3):1-14. doi: 10.1089/ars.2021.0029. Epub 2021 Dec 17.